Drug Profile

Devimistat - Cornerstone Pharmaceuticals Inc

Alternative Names: 6,8-bis(benzylthio)octanoic-acid; Bylantra; CPI-613; ONO-7912

Latest Information Update: 11 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cornerstone Pharmaceuticals; Stony Brook University
Developer Case Comprehensive Cancer Center; Cornerstone Pharmaceuticals Inc; National Cancer Institute (USA); Ono Pharmaceutical; University of Michigan; Wake Forest University Health Sciences; Wake Forest University School of Medicine
Class Antineoplastics; Carboxylic acids; Coenzymes; Fatty acids; Small molecules; Sulfides
Mechanism of Action Ketoglutarate dehydrogenase complex inhibitors; Pyruvate dehydrogenase complex inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Myelodysplastic syndromes; Burkitt's lymphoma; Biliary cancer; Acute myeloid leukaemia; Soft tissue sarcoma; Pancreatic cancer; Peripheral T-cell lymphoma; T-cell lymphoma
New Molecular Entity Yes

Phase III Acute myeloid leukaemia; Pancreatic cancer
Phase II B-cell lymphoma; Burkitt's lymphoma; Small cell lung cancer; Solid tumours; T-cell lymphoma
Phase I/II Biliary cancer; Cancer; Clear cell sarcoma; Colorectal cancer
No development reported Hodgkin's disease
Discontinued Myelodysplastic syndromes

25 Aug 2026 Rafael Pharmaceuticals completes a phase II trial in Burkitt's lymphoma, B-cell lymphoma (In adolescents, In adults, In the elderly, Second-line therapy or greater) in USA (IV) (NCT03793140)
28 Jul 2026 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
28 Jul 2026 No recent reports of development identified for phase-I development in Hodgkin's-disease(Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in USA (IV)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com